|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 318.00 SEK | -0.87% |
|
+6.21% | +2.32% |
| Mar. 11 | BioArctic partner to present long-term lecanemab data at AD/PD conference | FW |
| Feb. 20 | Nordea Raises Price Target for Bioarctic to 240 Kronor (236), Reiterates Sell | FW |
| Capitalization | 28.21B 3.06B 2.64B 2.39B 2.28B 4.16B 282B 4.28B 11.25B 135B 11.48B 11.24B 486B | P/E ratio 2025 |
27x | P/E ratio 2026 * | 482x |
|---|---|---|---|---|---|
| Enterprise value | 26.22B 2.84B 2.46B 2.22B 2.12B 3.87B 262B 3.98B 10.45B 125B 10.67B 10.44B 452B | EV / Sales 2025 |
13.8x | EV / Sales 2026 * | 22.5x |
| Free-Float |
44.08% | Yield 2025 * |
-
| Yield 2026 * | 0.63% |
Last Transcript: BioArctic AB
| 1 day | -0.87% | ||
| 1 week | +6.21% | ||
| Current month | +2.98% | ||
| 1 month | -0.06% | ||
| 3 months | -1.00% | ||
| 6 months | +15.13% | ||
| Current year | +2.32% |
| 1 week | 286.6 |  | 325.6 |
| 1 month | 286.6 | | 364.4 |
| Current year | 284 | | 364.4 |
| 1 year | 154.4 | | 364.4 |
| 3 years | 137.7 | | 392 |
| 5 years | 66.7 | | 392 |
| 10 years | 20.4 | | 392 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2012-12-31 | |
| Director of Finance/CFO | 55 | 2023-05-31 | |
Johanna Fälting
CTO | Chief Tech/Sci/R&D Officer | 54 | 2011-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 79 | 2003-01-23 | |
| Chairman | 77 | 2003-01-27 | |
Eugen Steiner
CHM | Chairman | 72 | 2023-05-31 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +0.41% | 1.25% | 4 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.87% | +6.21% | +57.58% | +21.84% | 3.06B | |
| -1.39% | -6.85% | -8.31% | -8.31% | 44.08B | |
| -2.12% | -0.04% | +21.65% | +38.23% | 33.16B | |
| +1.46% | +5.88% | +18.52% | +47.53% | 30.96B | |
| +0.38% | -3.54% | -6.49% | -13.02% | 28.8B | |
| +0.74% | -1.58% | +156.08% | +379.72% | 19.74B | |
| -5.41% | -5.75% | +56.22% | +114.20% | 13.96B | |
| +2.34% | +2.55% | +46.60% | +172.31% | 13.56B | |
| -0.75% | -5.48% | +25.26% | -0.38% | 12.88B | |
| -1.15% | -5.87% | +126.43% | +120.23% | 12.35B | |
| Average | -0.68% | -2.15% | +49.35% | +87.24% | 21.26B | |
| Weighted average by Cap. | -0.62% | -3.02% | +34.34% | +70.43% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 1.99B 216M 187M 169M 161M 294M 19.94B 302M 795M 9.53B 811M 794M 34.34B | 1.23B 133M 115M 104M 99.54M 181M 12.3B 187M 490M 5.88B 501M 490M 21.19B |
| Net income | 1B 109M 93.85M 84.73M 81.03M 148M 10.02B 152M 399M 4.79B 408M 399M 17.25B | 286M 31.04M 26.82M 24.21M 23.16M 42.21M 2.86B 43.4M 114M 1.37B 116M 114M 4.93B |
| Net Debt | -1.99B -216M -187M -168M -161M -294M -19.92B -302M -794M -9.52B -810M -793M -34.3B | -568M -61.58M -53.22M -48.04M -45.95M -83.75M -5.68B -86.11M -226M -2.72B -231M -226M -9.78B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-03-11 | 318.00 kr | -0.87% | 125,514 |
| 26-03-10 | 320.80 kr | +7.08% | 226,360 |
| 26-03-09 | 299.60 kr | +0.27% | 162,475 |
| 26-03-06 | 298.80 kr | -0.40% | 154,136 |
| 26-03-05 | 300.00 kr | +0.20% | 125,207 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIOA B Stock
Select your edition
All financial news and data tailored to specific country editions
